Evidence map›Paper›PMID 32938720›Full record

ArticleMolecular pharmacology2020

Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism.

Sonia J Parikh, Chiara M Evans, Juliet O Obi, Qinghai Zhang, Keiko Maekawa, Karen C Glass, Manish B Shah

Open access · bronzeAbstract read
In one paragraph

Article in Molecular pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Drug Metabolism: A Half-Century Plus of Progress, Continued Needs, and New Opportunities.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Article
  6. Article
  7. Four Decades of Cytochrome P450 2B Research: From Protein Adducts to Protein Structures and Beyond.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Review
  8. Silencing ofInsects · 2022
    Article
  9. Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Sonia J ParikhDepartment of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York (S.J.P., C.M.E., J.O.O., K.C.G., M.B.S.); Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California (Q.Z.); and Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kodo, Kyotanabe, Kyoto, Japan (K.M.).
Chiara M EvansDepartment of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York (S.J.P., C.M.E., J.O.O., K.C.G., M.B.S.); Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California (Q.Z.); and Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kodo, Kyotanabe, Kyoto, Japan (K.M.).
Juliet O ObiDepartment of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York (S.J.P., C.M.E., J.O.O., K.C.G., M.B.S.); Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California (Q.Z.); and Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kodo, Kyotanabe, Kyoto, Japan (K.M.).
Qinghai ZhangDepartment of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York (S.J.P., C.M.E., J.O.O., K.C.G., M.B.S.); Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California (Q.Z.); and Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kodo, Kyotanabe, Kyoto, Japan (K.M.).
Keiko MaekawaDepartment of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York (S.J.P., C.M.E., J.O.O., K.C.G., M.B.S.); Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California (Q.Z.); and Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kodo, Kyotanabe, Kyoto, Japan (K.M.).
Karen C GlassDepartment of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York (S.J.P., C.M.E., J.O.O., K.C.G., M.B.S.); Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California (Q.Z.); and Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kodo, Kyotanabe, Kyoto, Japan (K.M.).
Manish B ShahDepartment of Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences, Albany, New York (S.J.P., C.M.E., J.O.O., K.C.G., M.B.S.); Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, California (Q.Z.); and Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kodo, Kyotanabe, Kyoto, Japan (K.M.) manish.shah@acphs.edu.
Albany College of Pharmacy and Health Sciences · USDoshisha Women's College of Liberal Arts · JP

Funding

X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6M
Mediating Membrane Protein Crystal Contacts by Stabilization ReagentsR01GM098538 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI ZHANG, QINGHAI · 2011 to 2015
$1.8M
NIGMS NIH HHS P41 GM103393NIGMS NIH HHS R01 GM098538
6 · The paper itself

Abstract

The human CYP2C9 plays a crucial role in the metabolic clearance of a wide range of clinical therapeutics. The *2 allele is a prevalent genetic variation in CYP2C9 that is found in various populations. A marked reduction of catalytic activity toward many important drug substrates has been demonstrated by CYP2C9*2, which represents an amino acid variation at position 144 from arginine to cysteine. The crystal structure of CYP2C9*2 in complex with an antihypertensive drug losartan was solved using X-ray crystallography at 3.1-Å resolution. The Arg144Cys variation in the *2 complex disrupts the hydrogen-bonding interactions that were observed between the side chain of arginine and neighboring residues in the losartan complex of CYP2C9 and the wild-type (WT) ligand-free structure. The conformation of several secondary structural elements is affected, thereby altering the binding and orientation of drug and important amino acid side chains in the distal active site cavity. The new structure revealed distinct interactions of losartan in the compact active site of CYP2C9*2 and differed in occupancy at the other binding sites previously identified in the WT-losartan complex. Furthermore, the binding studies in solution using losartan illustrated lower activity of the CYP2C9*2 compared with the WT. Together, the findings yield valuable insights into the decreased hydroxylation activity of losartan in patients carrying CYP2C9*2 allele and provide a useful framework to investigate the effect of a single-nucleotide polymorphism that leads to altered metabolism of diverse drug substrates. SIGNIFICANCE STATEMENT: The *2 allele of the human drug-metabolizing enzyme CYP2C9 is found in different populations and results in significantly reduced activity toward various drug substrates. How the CYP2C9*2 variant induces altered drug metabolism is poorly understood given that the Arg144Cys variation is located far away from the active site. This work yield insight into the effect of distal variation using multitude of techniques that include X-ray crystallography, isothermal titration calorimetry, enzymatic characterization, and computational studies.

Indexed as

AllelesAntihypertensive AgentsCatalytic DomainCytochrome P-450 CYP2C9HumansLosartanPolymorphism, Single NucleotideAntihypertensive AgentsCYP2C9 protein, humanCytochrome P-450 CYP2C9Losartan

Identifiers

PMID32938720
PMCPMC7569312
OpenAlexW3087149172

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.